Mar 7 |
Earnings Scheduled For March 7, 2024
|
Mar 5 |
Chemomab Therapeutics to Participate in Leerink Global BioPharma Conference
|
Feb 20 |
What's Going On With Fibro-Inflammatory Disease Focused Chemomab Therapeutics On Tuesday?
|
Feb 20 |
Chemomab Awarded New Patents for CM-101, Its First-in Class Monoclonal Antibody in Clinical Development for Fibro-Inflammatory Diseases
|
Feb 14 |
Chemomab Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update
|
Feb 5 |
Chemomab Therapeutics to Participate in Upcoming Investor Conferences
|
Jan 30 |
Chemomab Therapeutics Announces New Publication Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis
|
Jan 3 |
Chemomab Announces Completion of Patient Enrollment in CM-101 Phase 2 Primary Sclerosing Cholangitis Trial and Moves Up Expected Topline Readout to Midyear 2024
|
Nov 16 |
Chemomab Presentation at ACR Convergence 2023 Provides Further Support for Key Role of Its CCL24 Target in the Pathogenesis of Systemic Sclerosis
|
Nov 15 |
Chemomab jumps on FDA Fast Track tag for liver disease therapy
|